Markets:

Overview

News

Currencies

International

Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

765.16 -10.37 (-1.34%)

Streaming Delayed Price Updated: 12:55 PM EDT, Apr 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

60 61 Next >

EYLEA HD® (aflibercept) Injection 8 mg Positive Phase 3 Results in Patients with Macular Edema following Retinal Vein Occlusion Presented at Angiogenesis Meeting

February 08, 2025

EYLEA HD led to improved vision with extended dosing intervals, achieving non-inferior vision gains with an every 8-week dosing regimen compared to EYLEA® (aflibercept) Injection 2 mg dosed every 4...

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Three-Year Results for EYLEA HD® (aflibercept) Injection 8 mg in Patients with Wet Age-related Macular Degeneration Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals

February 08, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Wall Street's Top 10 Stock Calls This Week - Saturday, Feb. 8 ↗

February 08, 2025

What has Wall Street been buzzing about this week? Here is a look at the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of Feb. 3-7, 2025.

Via Talk Markets

Topics Stocks / Equities

Beyond The Numbers: 18 Analysts Discuss Regeneron Pharmaceuticals Stock ↗

January 28, 2025

Via Benzinga

Looking Into Regeneron Pharmaceuticals's Recent Short Interest ↗

January 24, 2025

Via Benzinga

Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years ↗

February 07, 2025

Via Benzinga

Regeneron Stock Down 30% Over Past 6 Months: Leerink Sees Buying Opportunity, Retail's On The Same Page ↗

February 06, 2025

The analyst sees 2025 as a challenging year due to Eylea headwinds but expects growth to accelerate in 2026, driven by strong eczema treatment sales from the company’s Dupixent drug.

Via Stocktwits

Billions in Buybacks: 4 Stocks Rewarding Shareholders Now

February 06, 2025

These stocks are looking to return varying amounts of capital to shareholders using buybacks. One fintech's buyback capacity is equal to 25% of its market cap.

Via MarketBeat

Arcutis Soared In 2024, Blazing Trails In Dermatology. Why Its CEO Eyes Bigger Gains. ↗

February 06, 2025

The company won three FDA approvals over the past two years. Now, it's angling for two new approvals in 2025.

Via Investor's Business Daily

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGN

February 05, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

Why Regeneron Pharmaceuticals Stock Topped the Market on Tuesday ↗

February 04, 2025

Via The Motley Fool

Uncover the latest developments among S&P500 stocks in today's session. ↗

February 04, 2025

Let's have a look at what is happening on the US markets one hour before the close of the markets on Tuesday. Below you can find the top S&P500 gainers and losers in today's session.

Via Chartmill

Discover which S&P500 stocks are making waves on Tuesday. ↗

February 04, 2025

Get insights into the S&P500 index performance on Tuesday. Explore the top gainers and losers within the S&P500 index in today's session.

Via Chartmill

Regeneron Pharma Q4 Earnings Crush Estimates, Initiates Dividend And Additional Stock Buyback Program ↗

February 04, 2025

Regeneron beat Q4 estimates with $12.07 EPS and $3.79B in sales. The company announced a dividend, a $3 billion buyback, and continued R&D investments.

Via Benzinga

US Stocks Rise Despite China's Trade Fears, Palantir Defies Gravity, Gold Rallies Further: What's Driving Markets Tuesday? ↗

February 04, 2025

U.S. stocks advanced midday Tuesday, demonstrating resilience despite escalating geopolitical tensions and trade uncertainties between the world’s two largest economies.

Via Benzinga

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals

February 04, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

Regeneron Advances On Fourth-Quarter Beat As Eylea Meets Expectations ↗

February 04, 2025

Regeneron stock rose early Tuesday on a strong fourth-quarter report that included in-line sales of eye drug Eylea.

Via Investor's Business Daily

Regeneron’s (NASDAQ:REGN) Q4 Sales Top Estimates, Stock Soars

February 04, 2025

Biotech company Regeneron (NASDAQ:REGN) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 10.3% year on year to $3.79 billion. Its non-GAAP profit of $12.07 per share...

Via StockStory

Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to ~$4.5 Billion

February 04, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Earnings Scheduled For February 4, 2025 ↗

February 04, 2025

Via Benzinga

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals

January 29, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

January 28, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

9 Health Care Stocks With Whale Alerts In Today's Session ↗

January 28, 2025

Via Benzinga

America’s Top 40 High School Scientists to Compete for $1.8 Million in Awards at Prestigious Regeneron Science Talent Search

January 23, 2025

The Regeneron Science Talent Search Celebrates and Rewards Today’s Most Talented Young Minds Driving Innovation and Progress through Scientific Exploration

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals

January 22, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

REGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

January 21, 2025

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

INVESTOR REMINDER: Berger Montague Notifies Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Investors of a Class Action Lawsuit and Deadline

January 21, 2025

From Berger Montague

Via GlobeNewswire

ROSEN, A RANKED AND LEADING FIRM, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGN

January 19, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

Robbins LLP Urges REGN Stockholders with Large Losses to Contact the Firm for Information About the Class Action Against Regeneron Pharmaceuticals, Inc

January 17, 2025

From Robbins LLP

Via GlobeNewswire

Stock Market Rises On Tame Inflation, Bank Earnings: Weekly Review ↗

January 17, 2025

Many stocks flashed buy signals as the major indexes rose to or above key levels.

Via Investor's Business Daily

Topics Economy

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

60 61 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Regeneron Pharmaceuticals (NQ:REGN)

All News about Regeneron Pharmaceuticals

Starting at $3.75/week.

Subscribe Today